rewrite this title and make it good for SEOWaystar to Acquire Iodine Software in $1.25B Deal to Enhance AI-Powered Healthcare Platform

Waystar Holding Corp. (NASDAQ:WAY) is one of the best IPO stocks to buy according to Wall Street analysts. On July 24, Waystar entered into a definitive agreement to acquire Iodine Software for an enterprise value of $1.25 billion. The deal is expected to be funded with an even split of cash and stock. Waystar shareholders will own ~92% of the new combined company, while Iodine equity holders will own about 8%.

Advent, which is the largest shareholder of Iodine, will receive Waystar shares and has agreed to an 18-month lock-up period post-closing. The acquisition is anticipated to close by the end of 2025, pending regulatory approvals. The acquisition aims to enhance Waystar’s cloud-based platform by integrating Iodine’s AI-powered clinical intelligence software.

A close-up of a hand tapping away at a keyboard, using the company’s software to carry out a transaction.

The combined entity is projected to serve 17 of the 20 US News Best Hospitals and increase Waystar’s total addressable market by over 15%. The integration will use Iodine’s AI engine, called IodineIQ, which trains on patient encounters and clinical data to automate tasks. The companies anticipate more than $15 million in cost synergies within the first two years after the closing.

Waystar Holding Corp. (NASDAQ:WAY) is a company that develops a cloud-based software solution for healthcare payments.

While we acknowledge the potential of WAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.